Clinical Pharmacology & Therapeutics

Papers
(The H4-Index of Clinical Pharmacology & Therapeutics is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Sodium Bicarbonate Prescription and Extracellular Volume Increase: Real‐world Data Results from the AlcalUN Study315
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation247
Issue Information221
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers207
ASCPT News132
In This Issue118
In this Issue112
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease109
108
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten105
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study92
Neurodegenerative Diseases: The Value of Early Predictive End Points91
Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement78
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence73
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance68
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter62
Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine62
Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population59
More Than Pharmacokinetics: Transporters in Clinical Pharmacology57
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”56
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”52
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination51
ICH S7B In Vitro Assays Do Not Address Mechanisms of QTC Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QTC Studies50
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors48
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective47
Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients46
Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis45
Longitudinal Model‐Based Meta‐Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma44
The Broader Context of Liquid Biopsy in Absorption, Distribution, Metabolism, and Elimination43
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example43
Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke42
Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs42
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers41
A Biological Basis for Pharmacokinetics: The Remote Sensing and Signaling Theory41
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization41
Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling41
Estimating Culprit Drugs for Adverse Drug Reactions Based on Bayesian Inference41
FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception40
The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities39
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience39
0.69859004020691